Zhitong Finance APP news, Yantai Dongcheng Biochemicals (002675.SZ)announcement, the company's controlling subsidiary, Yantai Lanna Cheng Biotechnology Co., Ltd. (referred to as 'Lanna Cheng') has received the Drug Clinical Trial Approval Notice for 18F-LNC1007 injection issued by the China National Medical Products Administration (NMPA), and will conduct clinical trials in the near future.

The company's research product, 18F-LNC1007 injection, is a novel dual-targeted radiopharmaceutical for in vivo diagnosis, targeting fibroblast activation protein (FAP) and integrin αvβ3 (αvβ3), intended for the diagnosis of FAP and αvβ3-positive solid tumors in adults.